Letairis Uptake “Excellent” In First Full Quarter, Gilead Exec Says
Sales of the PAH drug, which competes with Actelion’s Tracleer, were around $6 million, but free-month offer is about to end.
Sales of the PAH drug, which competes with Actelion’s Tracleer, were around $6 million, but free-month offer is about to end.